Department of Urology, Ruijin Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Urology. 2010 Mar;75(3):547-50. doi: 10.1016/j.urology.2009.09.078.
To evaluate the efficacy of intravesical instillation of hyaluronic acid (HA) after hydrodistention for the treatment of patients with interstitial cystitis (IC) having small bladder capacity.
A total of 47 patients with IC (aged 27-76 years) whose functional bladder capacity was less than 200 mL received bladder hydrodistention. Thereafter, 20 patients received intravesical instillation of 40 mg HA weekly in the first month and then monthly in the following 2 months. Sixteen patients received intravesical heparin instead and 11 patients received hydrodistention alone as the control. Mean voids per day, visual analog scale for pain, and functional bladder capacity were measured before hydrodistention and 3 and 6 months after hydrodistention in all 3 groups and 9 months after hydrodistention in HA and heparin groups.
Two patients in the HA group and 1 in the heparin group failed to complete the treatment. Three months after hydrodistention, there was no improvement in the control group. Six and 9 months after hydrodistention, rate of improvement was significantly higher in the HA group than in the heparin group (77.8% vs 33.3%, P < .05; 50% vs 20%, P < .05). At 9 months, heparin treatment did not show any improvement. Improvement in voids per day (-1.8 +/- 2.5, P < .01), visual analog scale (-0.9 +/- 1.1, P < .01), and bladder capacity (16 +/- 18 mL, P < .01) was still significant in the HA group.
Intravesical instillation of HA may obviously prolong the effect of bladder hydrodistention in patients with severe IC. Its effect was better than heparin.
评估膀胱水扩张后膀胱内注射透明质酸(HA)治疗膀胱容量小的间质性膀胱炎(IC)患者的疗效。
共 47 例 IC 患者(年龄 27-76 岁),其功能性膀胱容量小于 200mL 接受膀胱水扩张。此后,20 例患者在第 1 个月每周接受 40mgHA 膀胱内灌注,然后在接下来的 2 个月每月灌注 1 次。16 例患者接受膀胱内肝素治疗,11 例患者仅接受水扩张作为对照。3 组患者均在水扩张前及水扩张后 3 个月和 6 个月测量每日平均排尿量、疼痛视觉模拟评分和功能性膀胱容量,HA 和肝素组在水扩张后 9 个月测量。
HA 组有 2 例和肝素组有 1 例患者未能完成治疗。水扩张后 3 个月,对照组无改善。水扩张后 6 个月和 9 个月,HA 组改善率明显高于肝素组(77.8%比 33.3%,P<0.05;50%比 20%,P<0.05)。9 个月时,肝素治疗没有改善。每日平均排尿量(-1.8+/-2.5,P<0.01)、疼痛视觉模拟评分(-0.9+/-1.1,P<0.01)和膀胱容量(16+/-18mL,P<0.01)仍有显著改善。
膀胱内注射 HA 可明显延长严重 IC 患者膀胱水扩张的疗效,其效果优于肝素。